![]() ![]() ![]() ![]() Despite some encouraging recent improvements in survival achieved through optimizing the sequencing of surgery and chemotherapy treatment regimens, developing new and effective therapeutic options remains a dire need for advanced-stage PDAC patients 6.Ĭytotoxic T lymphocyte (CTL)-based immunotherapies have been successful at inducing objective clinical responses in a variety of cancer types 7. Progress toward effective treatment has been slow and the incidence of PDAC-related deaths has continued to rise 4, 5. Early detection is unusual, with 85% of patients presenting with locally advanced or metastatic disease 3. Pancreatic ductal adenocarcinoma (PDAC), the most aggressive form of pancreatic cancer, remains notorious for its poor prognosis and high mortality rate, with its overall 5-year survival rate of 8% being amongst the lowest of all cancer types 1, 2. Gene expression profiling reveals VGLL1 as a member of a unique group of cancer-placenta antigens (CPA) that may constitute immunotherapeutic targets for patients with multiple cancer types. Here we show that VGLL1-specific CTLs expanded from the blood of a PDAC patient could recognize and kill in an antigen-specific manner a majority of HLA-A*0101 allogeneic tumor cell lines derived not only from PDAC, but also bladder, ovarian, gastric, lung, and basal-like breast cancers. This identified a shared HLA-A*0101 restricted peptide derived from co-transcriptional activator Vestigial-like 1 (VGLL1) as a putative TAA demonstrating overexpression in multiple tumor types and low or absent expression in essential normal tissues. To expand the TAA landscape of pancreatic ductal adenocarcinoma (PDAC), we performed tandem mass spectrometry analysis of HLA class I-bound peptides from 35 PDAC patient tumors. ![]() Nature Communications volume 11, Article number: 5332 ( 2020)Ĭytotoxic T lymphocyte (CTL)-based cancer immunotherapies have shown great promise for inducing clinical regressions by targeting tumor-associated antigens (TAA). Vestigial-like 1 is a shared targetable cancer-placenta antigen expressed by pancreatic and basal-like breast cancers ![]()
0 Comments
Leave a Reply. |